Abstract
Overview
Introduction
This analysis examines the historical and forecast performance for
Sanofi-Aventis in the ethical pharma sector. The profile encompasses global
company strategy, portfolio and pipeline analysis and assessment of financial
performance, with 1-6 year sales forecasts for key drugs. An interactive
forecasting and analysis tool provides continually updated quantitative and
qualitative information.
Reasons to Purchase
- Benchmark Sanofi-Aventis' s performance against key rivals in the ethical
pharmaceutical sector
- See how, as 2012 approaches, the company' s mature core product portfolio
will face an increased risk of generic exposure, hampering sales growth
- Evaluate the prospects of the Sanofi-Aventis' s late-stage pipeline, which
must fulfill its potential if growth is to be sustained in the long term
View Cart
